LEADER 04993nam 2201249z- 450 001 9910557436403321 005 20210501 035 $a(CKB)5400000000043359 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68985 035 $a(oapen)doab68985 035 $a(EXLCZ)995400000000043359 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aSemisolid Dosage 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (182 p.) 311 08$a3-03936-948-2 311 08$a3-03936-949-0 330 $aEven in ancient times, semi-solid preparations for cutaneous application, popularly known as ointments, played an important role in human society. An advanced scientific investigation of "ointments" as dosage forms was initiated in the 1950s. It was only from then on that the intensive physico-chemical characterization of ointments as well as the inclusion of dermatological aspects led to a comprehensive understanding of the various interactions between the vehicle, the active ingredient and the skin. From then on, many researchers were involved in optimizing semi-solid formulations with respect to continuously changing therapeutic and patient needs. Aspects that have been dealt with were the optimization of dermato-biopharmaceutical properties and many different issues related to patient compliance, such as skin tolerance, applicability, and cosmetic appeal. Moreover, processing technology has been improved and analytical techniques were developed and refined in order to enable the improved characterization of the formulation itself as well as its interaction with the skin. This Special Issue serves to highlight and capture the contemporary progress and current research on semi-solid formulations as dermal drug delivery systems. We invite articles on all aspects of semi-solid formulations, highlighting the research currently undertaken to improve and better understand these complex drug delivery systems with respect to their formulation, processing and characterization issues. 606 $aMedicine and Nursing$2bicssc 610 $aacceptance criteria 610 $aAmphotericin B 610 $aantibacterial 610 $abirch bark extract 610 $abudesonide 610 $achitosan 610 $acompounded preparation 610 $aconfocal Raman spectroscopy (CRS) 610 $acurcumin 610 $acutaneous leishmaniasis 610 $adeformable liposomes 610 $adermal delivery 610 $adermal drug delivery 610 $adiffusion cell 610 $adiscriminatory ability 610 $adrug delivery 610 $aeosinophilic esophagitis 610 $aesophagus permeability 610 $aFDA's SUPAC-SS guidance 610 $aFranz diffusion 610 $agel strength 610 $aguar gum 610 $ahuman excised skin 610 $ahydrogel 610 $ahydrogen bonding 610 $ain situ hydrogel-forming powder 610 $ain vitro 610 $ain vitro permeation 610 $aintercellular lipids 610 $aIVRT 610 $aJurkat cells 610 $aLeishmania infantum 610 $aliposome surface charge 610 $amethadone 610 $amethyl cellulose 610 $ametronidazole 610 $amucoadhesion 610 $an/a 610 $ananocarrier 610 $ananogels 610 $aniacinamide 610 $anitric oxide-releasing formulation 610 $anon-ionic emulsifiers 610 $anonivamide 610 $aoleogels 610 $apain 610 $aPAMPA 610 $apediatric medicine 610 $apermeation 610 $apolyethylene glycol alkyl ethers 610 $apolyethylene glycol sorbitan fatty acid esters 610 $aporcine skin 610 $apositive and negative controls 610 $arheological characterization 610 $arheology 610 $aS-nitrosoglutathione (GSNO) 610 $asameness 610 $asemisolid dosage forms 610 $aSepigel 305® 610 $askin 610 $askin penetration 610 $aSkin-PAMPA 610 $asolvent 610 $aStrat-M® membrane 610 $asubstantivity 610 $atacrolimus formulation 610 $athermogel 610 $atopical cream 610 $atopical treatment 610 $atriterpene 610 $awound dressing 610 $awound healing 610 $awound therapy 610 $axanthan gum 615 7$aMedicine and Nursing 700 $aDaniels$b Rolf$4edt$01297536 702 $aLunter$b Dominique$4edt 702 $aDaniels$b Rolf$4oth 702 $aLunter$b Dominique$4oth 906 $aBOOK 912 $a9910557436403321 996 $aSemisolid Dosage$93024510 997 $aUNINA